Literature DB >> 11150947

The incidence of pharmacologically induced priapism in the diagnostic and therapeutic management of 685 men with erectile dysfunction.

P Perimenis1, A Athanasopoulos, I Geramoutsos, G Barbalias.   

Abstract

OBJECTIVE: To evaluate the incidence of pharmacologically induced priapism in the diagnostic and therapeutic management of erectile dysfunction. PATIENTS AND METHODS: Over a period of 7 years, 685 men were investigated for erectile failure. They underwent a simple test with vaso-active drugs, and the nonresponders were further investigated. Eventually, 83 men began autoinjections and 45 still continue.
RESULTS: Eight (1.2%) cases of priapism presented during the simple test with vaso-active drugs in these patients, while none occurred during self-injection treatment. Three were prolonged erections induced by prostaglandin E1 (PGE1) and 5 by papaverine (Pap). Six were treated safely with intracavernosal injection of etilephrine without blood aspiration.
CONCLUSION: Priapism is always a potential phenomenon where no individual, no particular drug and no specific dose are completely safe. It may be caused even with 5 microg of PGE1 or 7.5 mg of Pap. Auto-injection therapy however is a safe kind of treatment in well-experienced patients. Careful regulation of the doses and practice in the use of vaso-active drugs may reduce the priapism rate.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11150947     DOI: 10.1159/000056558

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  4 in total

Review 1.  Evaluation and management of priapism: 2009 update.

Authors:  Yun-Ching Huang; Ahmed M Harraz; Alan W Shindel; Tom F Lue
Journal:  Nat Rev Urol       Date:  2009-05       Impact factor: 14.432

Review 2.  Prophylactic phenylephrine for iatrogenic priapism: a pilot study with Peyronie's patients.

Authors:  Pengbo Jiang; Athena Christakos; Mina Fam; Hossein Sadeghi-Nejad
Journal:  Korean J Urol       Date:  2014-10-10

3.  Methylene blue as a means of treatment for priapism caused by intracavernous injection to combat erectile dysfunction.

Authors:  J Hübler; A Szántó; K Könyves
Journal:  Int Urol Nephrol       Date:  2003       Impact factor: 2.370

Review 4.  What is the current role of intracavernosal injection in management of erectile dysfunction?

Authors:  A I El-Sakka
Journal:  Int J Impot Res       Date:  2016-04-14       Impact factor: 2.896

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.